Dr. Megan Coylewright Named Editor of CardioSmart

Megan Coylewright, MD, MPH, FACC, has been named editor of the American College of Cardiology’s CardioSmart patient engagement initiative, which aims to support the patient and clinician partnership to personalize care. Coylewright will serve a three-year term.

“The role of editor of CardioSmart is an ideal blend of my daily clinical work performing transcatheter valve repair and replacement, research in shared decision making, and our community and nationally-based efforts to ensure we are using best practices in promoting diversity, inclusion and belonging in all that we do,” Coylewright said. “I am thrilled to work with the talented staff of CardioSmart. Together, we will partner with patients and the cardiovascular care team to further embed the patient voice in our daily practices, scholarship, guidelines and clinical trials.”

Through CardioSmart.org, patients and clinicians can find information about heart conditions, resources to support important health care conversations and tools to build their partnership—not just on specific decisions, but over a lifetime. CardioSmart is a direct reflection of the ACC’s Core Values: Patient-Centered, Teamwork and Collaboration, and Professionalism and Excellence. As editor, Coylewright will be responsible for advising and ensuring clinical accuracy of the editorial content development on CardioSmart.org, as well as assist in developing innovative strategies to help the ACC best engage, educate and activate the diversity of cardiovascular patients in their care.

Trained as a structural interventional cardiologist, Coylewright is the vice chief of cardiology faculty development and director of the Structural Heart Program at Erlanger Health System in Chattanooga, Tennessee. Coylewright focuses on minimally invasive treatment options for heart disease. She is also committed to creating partnerships between clinicians and patients using shared decision-making to ensure patients meaningfully participate in informed care decisions that are right for them. Coylewright champions efforts both locally and nationally to increase diversity and inclusion in interventional cardiology, as well as amongst patients enrolled in clinical trials.

Prior to her current role, Coylewright completed her medical school, residency and public health training at Johns Hopkins University in Baltimore. While there, she also served as the health disparities coordinator at the Baltimore City Public Health Department. She completed an additional five years of training in cardiology, interventional cardiology and structural heart interventions at Mayo Clinic.

Coylewright is a Fellow of the American College of Cardiology and was selected for the ACC Emerging Faculty Program in 2014. She has made many contributions to the ACC thus far, including leading the shared decision-making section of the Championing Care initiative for patients with severe aortic stenosis from 2012-2014; serving on the Annual Scientific Session Program Committee from 2019-2022; and co-authoring the Diversity, Equity, Inclusion and Belonging section of the 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics report.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.